Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer

Chantal A. Lebbink; Eef G. WM Lentjes; Wim J. E. Tissing; Marry M. van den Heuvel-Eibrink; Hanneke M. van Santen; Elvira C. van Dalen

doi:10.1002/14651858.CD013805

Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer

Chantal A. Lebbink^*
, Eef G. WM Lentjes
, Wim J. E. Tissing
, Marry M. van den Heuvel-Eibrink
, Hanneke M. van Santen
, Elvira C. van Dalen

^*Corresponding author for this work

Utrecht University
University Medical Center Utrecht
Professor, Princess Maxima Center for pediatric oncology, PO Box 85090, Utrecht 3508 AB, the Netherlands

Research output: Contribution to journal › Article › Academic › peer-review

8 Downloads (Pure)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

Original language	English
Article number	CD013805
Journal	Cochrane Database of Systematic Reviews
Volume	2020
Issue number	12
DOIs	https://doi.org/10.1002/14651858.CD013805
Publication status	Published - 14 Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/14651858.CD013805

Thyroid-dysfunction-during-treatment-with-systemic-antineoplastic-therapy-for-childhood-cancer.pdfFinal published version, 135 KBLicence: Taverne

Cite this

@article{0a78f9b7af964e7a8d6a02b9c5ec054b,

title = "Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.",

author = "Lebbink, \{Chantal A.\} and Lentjes, \{Eef G. WM\} and Tissing, \{Wim J. E.\} and \{van den Heuvel-Eibrink\}, \{Marry M.\} and \{van Santen\}, \{Hanneke M.\} and \{van Dalen\}, \{Elvira C.\}",

year = "2020",

month = dec,

day = "14",

doi = "10.1002/14651858.CD013805",

language = "English",

volume = "2020",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd.",

number = "12",

}

TY - JOUR

T1 - Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer

AU - Lebbink, Chantal A.

AU - Lentjes, Eef G. WM

AU - Tissing, Wim J. E.

AU - van den Heuvel-Eibrink, Marry M.

AU - van Santen, Hanneke M.

AU - van Dalen, Elvira C.

PY - 2020/12/14

Y1 - 2020/12/14

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To gain insight into the occurrence of and risk factors for aberrant thyroid function parameters (i.e. TSH, free thyroxine (FT4)) as expression of hypothyroidism, hyperthyroidism, or NTI during cancer treatment in children treated with systemic antineoplastic therapy.

UR - https://www.scopus.com/pages/publications/85103068896

U2 - 10.1002/14651858.CD013805

DO - 10.1002/14651858.CD013805

M3 - Article

SN - 1465-1858

VL - 2020

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 12

M1 - CD013805

ER -

Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this